Cost of Goods (COGS) modeling and Techno-Economic Analysis (TEA) — also known as Techno-Economic Assessment — are critical components in the commercialization of advanced therapies, biologics, vaccines, cell and gene therapies, cultivated cell-based nutrition, dermocosmetics, and other bioindustries.
These analyses underpin Healthcare Technology Assessments (HTAs), which ultimately influence reimbursement pathways, government and private insurance coverage, national subsidy and co-payment programs, pricing strategy, long-term market adoption, and ultimately patient access.
In biotechnology, the process is often the product. Selecting a technology during early development that is not linearly scalable into commercial manufacturing can result in costly delays, inefficient capital deployment, underutilization of grant or investor funding, prolonged time-to-market, reduced competitiveness against alternative modalities, and a shortened effective patent life. For a blockbuster drug or therapy, every year of lost exclusivity can cost billions of dollars in foregone revenue — a branded drug generating US$3 billion annually loses approximately US$8.2 million per day of market exclusivity, with revenue typically declining by 80–90% within the first year of generic entry following patent expiry.
(Reference: DrugPatentWatch — Maximizing Pharmaceutical Patent Longevity: A Mechanistic and Strategic Guide to IP Term Extension and Lifecycle Fortification)
Early manufacturing missteps may significantly impact commercialization timelines and reduce the available market opportunity window. A rigorous and accurate COGS/TEA strategy is therefore essential to ensuring long-term commercial success. It provides a clear understanding of manufacturing economics, scalability, pricing structures, reimbursement alignment, and operational efficiency while enabling high-yield, cost-effective production.
Esco Aster utilizes proprietary financial and manufacturing models
leveraging both our linearly scalable Tide Motion® bioreactor technologies
and third-party manufacturing platforms to evaluate:
Our analyses support strategic decision-making for companies evaluating whether to:
A robust COGS/TEA assessment provides the economic justification and financial rigor for mission-critical business decisions, derisking investment while supporting long-term investment milestones, commercialization readiness, investor confidence, fundraising preparedness, and sustainable healthcare economics.
Where appropriate, Esco Aster can further support commercialization through our MSAT-as-a-Service offerings, helping clients refine process technologies to achieve target manufacturing economics and lower COGS.
COGS and TEA analyses influence strategic decisions across the entire product lifecycle:
COGS modeling is particularly important when evaluating manufacturing strategies such as:
Beyond manufacturing decisions, quality control and compliance strategies can also significantly impact product economics. These considerations may include:
COGS and TEA analyses are also critical in determining sustainable product pricing strategies capable of recouping R&D investments while supporting reimbursement and market adoption. This is especially relevant in cell and gene therapy, where development costs are often substantial, spanning:
Although the precise cost drivers underlying cell and gene therapy R&D cannot be fully determined from SEC filings alone, it is hypothesized that one of the principal contributors to elevated development costs is the highly complex and specialized manufacturing infrastructure and processes required to produce these therapies.
(Reference:
Choi et al., 2023 — PubMed)
A well-structured COGS assessment enables companies to:
Collectively, this enables more strategic, capital-efficient research, development, clinical, and manufacturing decisions, while serving as a critical component of investor pitch decks, business plans, fundraising strategies, and commercialization roadmaps.
Esco Aster provides integrated COGS analysis and Techno-Economic Assessments utilizing:
COGS/TEA analysis can also provide insights into which facility type is best suited to a client’s process, budget, and investment milestones. This includes evaluating whether to build an in-house cell processing facility, partner with a CRDMO/CMO, or adopt a hybrid approach that may involve initial outsourcing while a commercial site is developed in parallel.
Manufacturing cost optimization is vital, as cell-based products and their derivatives often involve complex unit operations, specialized cell processing facilities, skilled biotechnicians, and experienced manufacturing scientists — all of which make cGMP manufacturing costs a key factor in commercialization success.
A COGS/TEA analysis may highlight opportunities for process optimization, true walk-away automation following consumable loading, AI-enabled autonomous manufacturing, and strategic outsourcing.
Through our Enterprise Solutions conceptual design services, Esco Aster develops:
These models are particularly valuable for:
Once the required client inputs are provided — or generated through Esco Aster Research Services — Esco Aster will deliver:
Manufacturing cost optimization is particularly important for advanced therapies due to:
A COGS/TEA assessment may identify opportunities for:
Grantors benefit by ensuring that funded technologies adopt scalable, economically sustainable manufacturing strategies that maximize capital efficiency and translational impact.
Biotech companies and startups can execute development programs with greater confidence using robust COGS/TEA models to:
Investors can move forward with greater confidence, supported by a clear use of proceeds and milestone-based investment structure. A robust COGS analysis provides visibility into the cost structure of the final commercialized product, ensuring it will be attractive to potential acquirers. It demonstrates financial acumen and improves stakeholder confidence across fundraising efforts and investor return planning.
COGS/TEA analyses can also assist acquirers in determining fair licensing fees and acquisition valuations, as well as benchmarking the final product cost against competitors across modalities — providing a powerful toolkit when used in conjunction with our Business Development as-a-service offering.
Academics, technology transfer offices, and IP stakeholders benefit from implementing linearly scalable manufacturing technologies from the earliest stages of development, improving translational potential, facilitating outward licensing, and strengthening commercialization readiness.
Ensuring that final patient costs for life-saving medicines and therapies remain affordable is especially important for single-payer insurance systems, government medical subsidy programs, and private insurers seeking to provide equitable access to medicines, vaccines, and therapies.
Esco Aster provides cost modeling insights utilizing high-throughput automation and time-motion studies to automate manual cell culture operations, typically delivered through our MSAT-as-a-Service and Research Services offerings.
Esco Aster can develop conceptual facility designs through digital twin modeling, with estimated CapEx based on the dose volumes required to meet specific cost targets, ensuring that the final product is viable for broad social implementation.
Automation is applicable to a variety of cell types, as well as 2D, spheroid, and embryoid body culture formats, particularly for induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs).
Esco Aster provides cost modeling, front-end engineering, and automation studies including:
Applicable cell types include:
Cost modeling for cell and gene therapy is particularly important to ensure that the final product remains cost-competitive against other drug modalities, including bispecific T-cell engagers, trispecific monoclonal antibodies, peptides, nuclear medicines, antibody–drug conjugates, and other conjugate therapies.
COGS modeling is essential to determine the competitiveness and scalability of:
We evaluate:
In human vaccines, cost modeling is important for determining healthcare economics and informing decisions on whether a vaccine should be included in a national health immunization program — weighed against the cost of pandemic or disease burden — or subsidized for specific populations such as the elderly (e.g., influenza vaccines) or adolescents (e.g., HPV vaccines for cancer prevention), where population-level implementation economics are a critical consideration.
Vaccine economics are critical in evaluating:
In veterinary and livestock health, manufacturing economics are critical to ensuring affordable access while reducing zoonotic disease risks.
Cost reduction is especially important in animal health to ensure broad access to affordable vaccines for both companion animals and livestock that support global food and nutrition systems. Beyond economics, effective vaccination programs are essential for preventing zoonotic disease transmission from animals to humans — increasingly pertinent given that over 90% of emerging human infectious diseases originate from animal sources. Maintaining control of viral threats through scalable and cost-effective vaccination strategies may help prevent future “Disease X” pandemics.
Companion animals are also playing an increasingly important societal role — not only as family members in modern households, but also as essential working animals across agriculture, military operations, security, mobility assistance for the visually impaired, and therapeutic care.
Esco Aster’s perfusion-enabled Tide Motion® bioreactor platform, combined with high-productivity adherent CHO/HEK antibody generation systems and integrated simulated moving bed (SMB) or real moving bed (RMB) columnless single-use continuous chromatography platforms, enables next-generation process intensification. This integrated approach supports higher productivity, lower cost of goods (COGS), a reduced facility footprint, and scalable continuous biomanufacturing for advanced animal health biologics and vaccines.
In veterinary and livestock applications, manufacturing economics are vital to:
Applications include:
With evolving regulatory pathways and reduced bridging study requirements in certain jurisdictions, process intensification and continuous manufacturing are becoming increasingly important for biosimilar and biobetter development.
Esco Aster supports:
Dermocosmetics — including cosmeceuticals, medicated cosmetics, and quasi-drugs — represent an emerging category of science-driven, clinically validated dermatology products.
For dermatology-driven cosmetic products, TEA modeling supports:
For cultivated nutrition, supplements, and nutraceuticals, achieving price parity is often critical to commercialization success.
COGS/TEA analysis helps to:
A comprehensive COGS and TEA strategy is not simply a financial exercise — it is a commercialization roadmap.
By integrating:
This service is also a critical component of:
Esco Aster can integrate COGS/TEA Analysis with the following service areas:
Research & Manufacturing Services
Business & Strategic Support
Consulting Services
Patent Exclusivity & Commercial Impact:
DrugPatentWatch — Maximizing Pharmaceutical Patent Longevity: A Mechanistic and Strategic Guide to IP Term Extension and Lifecycle Fortification
Cell & Gene Therapy R&D Cost Estimation:
Choi et al. (2023) — R&D investment required for cell and gene therapy commercialization. PubMed (PMID: 37286928)
Healthcare Technology Assessment:
Agency for Care Effectiveness (ACE) — Singapore HTA
This document is intended for informational purposes only and is subject to change without notice. © Esco Aster Pte Ltd. All rights reserved.